OCX Stock Forecast 2025-2026
Distance to OCX Price Targets
OCX Price Momentum
🤔 Considering Oncocyte (OCX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest OCX Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, OCX has a neutral consensus with a median price target of $4.13 (ranging from $4.00 to $4.25). The overall analyst rating is Buy (6.7/10). Currently trading at $3.74, the median forecast implies a 10.3% upside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mike Matson at Needham, projecting a 13.6% upside. Conversely, the most conservative target is provided by Mason Carrico at Stephens & Co., suggesting a 7.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OCX Analyst Ratings
OCX Price Target Range
Latest OCX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OCX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2024 | Needham | Mike Matson | Buy | Reiterates | $4.25 |
| Oct 15, 2024 | Needham | Mike Matson | Buy | Reiterates | $4.25 |
| Aug 9, 2024 | Needham | Mike Matson | Buy | Reiterates | $4.25 |
| May 16, 2024 | Needham | Mike Matson | Buy | Reiterates | $4.25 |
| Apr 24, 2024 | Needham | Mike Matson | Buy | Maintains | $4.25 |
| Apr 17, 2024 | Stephens & Co. | Mason Carrico | Equal-Weight | Reiterates | $4.00 |
| Apr 15, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $5.00 |
| Nov 13, 2023 | Piper Sandler | David Westenberg | Neutral | Maintains | $3.00 |
| Nov 9, 2023 | Needham | Mike Matson | Buy | Maintains | $3.60 |
| Aug 24, 2023 | Benchmark | Bruce Jackson | Speculative Buy | Maintains | $5.00 |
| Aug 15, 2023 | Piper Sandler | David Westenberg | Neutral | Maintains | $3.50 |
| Aug 10, 2023 | Needham | Mike Matson | Buy | Maintains | $4.25 |
| Apr 4, 2023 | Needham | Mike Matson | Buy | Maintains | $0.45 |
| Dec 1, 2022 | Lake Street | Thomas Flaten | Hold | Downgrade | $0.50 |
| Nov 18, 2022 | Piper Sandler | David Westenberg | Neutral | Downgrade | $0.50 |
| Nov 14, 2022 | Piper Sandler | David Westenberg | Overweight | Maintains | $1.00 |
| Nov 11, 2022 | Needham | Mike Matson | Buy | Maintains | $1.40 |
| Aug 18, 2022 | Piper Sandler | Overweight | Maintains | $0.00 | |
| Aug 17, 2022 | Piper Sandler | David Westenberg | Overweight | Maintains | $1.50 |
| Aug 11, 2022 | Lake Street | Thomas Flaten | Buy | Maintains | $3.00 |
Oncocyte Corporation (OCX) Competitors
The following stocks are similar to Oncocyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Oncocyte Corporation (OCX) Financial Data
Oncocyte Corporation has a market capitalization of $106.96M with a P/E ratio of -1.0x. The company generates $709,000 in trailing twelve-month revenue with a 27.5% profit margin.
Revenue growth is -73.2% quarter-over-quarter, while maintaining an operating margin of -5,543.5% and return on equity of -165.3%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Oncocyte Corporation (OCX) Business Model
About Oncocyte Corporation
Develops molecular diagnostic tests for cancer detection.
Oncocyte generates revenue by creating and selling advanced genomic testing technologies that aid in cancer diagnosis and monitoring. The company targets healthcare providers and institutions, offering tests that provide precise information to support informed treatment decisions, thus enhancing patient outcomes.
Operating in the oncology and precision medicine sectors, Oncocyte aims to address the limitations of existing diagnostic methods with innovative and less invasive alternatives. Their focus on unmet needs in cancer diagnosis positions them to make significant contributions to patient care and clinical outcomes in the healthcare market.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
43
CEO
Mr. Joshua Riggs
Country
United States
IPO Year
2016
Website
www.oncocyte.comOncocyte Corporation (OCX) Latest News & Analysis
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
1 month agoOncocyte Corp. CEO Josh Riggs and CFO Andrea James will attend the BTIG MedTech Conference in Snowbird, Utah, on February 11, 2025.
Oncocyte's participation in a key industry conference highlights its visibility and potential partnerships, influencing investor sentiment and stock performance in the diagnostics sector.
Oncocyte Prices $29.1 Million Equity Offering
1 month agoOncocyte Corp. (Nasdaq: OCX) announced a registered direct offering and concurrent private placement with existing investors on February 10, 2025.
Oncocyte Corp's registered direct offering and PIPE can provide immediate capital for growth, but may dilute existing shares, impacting stock value and investor sentiment.
Oncocyte Corp. (NASDAQ: OCX) appointed Dr. Paul Billings as Consulting Chief Medical Officer to enhance regulatory support and business development in precision medicine.
Dr. Billings' expertise in diagnostics and commercialization can enhance Oncocyte Corp.'s product development, regulatory success, and partnerships, potentially boosting investor confidence and stock performance.
Medicare has expanded coverage for Oncocyte's assay, which aids in early detection of transplant rejection in kidney patients with donor-specific antibodies, potentially benefiting over 10,000 patients annually.
Expansion of Medicare coverage for Oncocyte's assay enhances patient outcomes and market potential, signaling growth opportunities for the company and related healthcare sectors.
Oncocyte Corp. (Nasdaq: OCX) executives, CEO Josh Riggs and CFO Andrea James, will attend the J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco.
Leadership attendance at major investor conferences can signal confidence in the company's direction and strategy, potentially influencing stock performance and investor sentiment.
Oncocyte Corp. (NASDAQ: OCX) announced the publication of favorable data for its DetermaCNI™ assay, which may impact investor sentiment positively.
Favorable data on Oncocyte's DetermaCNI™ assay may boost investor confidence, potentially increasing stock value and market interest in the company's diagnostic technology.
Frequently Asked Questions About OCX Stock
What is Oncocyte Corporation's (OCX) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Oncocyte Corporation (OCX) has a median price target of $4.13. The highest price target is $4.25 and the lowest is $4.00.
Is OCX stock a good investment in 2025?
According to current analyst ratings, OCX has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.74. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OCX stock?
Wall Street analysts predict OCX stock could reach $4.13 in the next 12 months. This represents a 10.3% increase from the current price of $3.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Oncocyte Corporation's business model?
Oncocyte generates revenue by creating and selling advanced genomic testing technologies that aid in cancer diagnosis and monitoring. The company targets healthcare providers and institutions, offering tests that provide precise information to support informed treatment decisions, thus enhancing patient outcomes.
What is the highest forecasted price for OCX Oncocyte Corporation?
The highest price target for OCX is $4.25 from Mike Matson at Needham, which represents a 13.6% increase from the current price of $3.74.
What is the lowest forecasted price for OCX Oncocyte Corporation?
The lowest price target for OCX is $4.00 from Mason Carrico at Stephens & Co., which represents a 7.0% increase from the current price of $3.74.
What is the overall OCX consensus from analysts for Oncocyte Corporation?
The overall analyst consensus for OCX is neutral. Out of 9 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $4.13.
How accurate are OCX stock price projections?
Stock price projections, including those for Oncocyte Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
